Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Keeping Track: Bad News For Bristol And Lilly, Good News For TG Therapeutics

Executive Summary

The latest drug development news and highlights from our US FDA Performance Tracker.
Advertisement

Related Content

Bristol Stuck In Waiting Game As Opdivo TMB Gamble Fails To Pay Off
Keeping Track: Pfizer’s Talzenna Ensures Record Year For Novel US Approvals; Novartis Submits SMA Gene Therapy
Pipeline Watch: Top-line Phase III Results For KX2-391, Dasotraline And Brigatinib
First-Line Chemo Combo Data Help Merck's Keytruda Power Past Opdivo
TMB Biomarker Is A Winding Path Rather Than Straight Road
Merck's Keytruda Enjoys Clean Sweep In Lung Cancer, At Bristol's Expense
Accelerated Approval: US FDA Defends Size Of Premarket Safety Databases, Confirmatory Endpoints
Keeping Track: Trulance Is First Novel Drug Of 2017; Vantrela ER Is Year's Second Abuse-Deterrent Opioid
Lilly's Lartruvo Scores Broad FDA Approval In Orphan Sarcomas
The ABCs Of Accelerated Approval Withdrawals

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS124648

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel